The University of Chicago is excited to be hosting a clinical trial ran by the universally known mesothelioma specialist, Dr. Hedy Kindler. Dr. Kindler will be utilizing an immunotherapy cancer drug, pembromizulab, in her clinical trial. While there are 90 clinical trials around the country that are testing this drug, Dr. Kindler’s trial will be the only one testing it on malignant mesothelioma.
Immunotherapy is considered the wave of the future for cancer treatments as it stimulates that body’s natural response against cancer, rather than depleting the body as chemotherapy and radiation can do.
Thus far, pembromizulab, has been proven to shrink tumors and work in a prolonged fashion, keeping the body from contracting new tumors.
The clinical trial is being offered to those suffering from pleural and peritoneal mesothelioma and is expected to run until 2018. Dr. Kindler’s team will administer pembromizulab intravenously every 21 days for 24 months. If the clinical trial proves successful, patients will also be eligible for another year of treatment with the drug.
Mesothelioma is a form of terminal cancer that typically affects the linings of the lungs or heart, but can also affect the lining of the abdomen or testicles. It is contracted when a person is exposed to asbestos, a heat-resistant compound that has been used in multiple industrial applications for centuries.
Employers were warned in the 1930s that asbestos exposure could harm their employees, yet many of them chose not to warn or protect their employees. This act of negligence means that these employers can be held liable for their employees getting mesothelioma.
At the Baltimore Law Office of Brown | Kiely, LLP, our mesothelioma lawyers can help you or your family file a lawsuit against an employer that didn’t protect you from asbestos. We have the experience you need to get you the compensation you deserve. Contact us today for a free consultation and to discuss how we get help you. Call us at (410) 625-9330.
